Chlorpheniramine (As Maleat)
- Chlorpheniramine (As Maleat)
- No Brand Name
- Tablet
- 4mg
- Blister
- 100 Tablets
-
• Allergic Rhinitis
Mechanism of Action
Histamine H1-receptor antagonist in blood vessels, respiratory tract, and gastrointestinal tract
Pharmacokinetics
Peak Plasma Time: 2-3 hr
Excretion: Urine
Contraindications
• Documented hypersensitivity
• Lower respiratory disease, eg, asthma
• Preemies & neonates
• Nursing women
• Acute asthma, sleep apnea
Adverse Reactions
Sedation ranging from mild drowsiness to deep sleep, Dizziness, Lassitude, Anorexia, Nausea, Vomiting, Diarrhea, Constipation, Arrhythmias, Hypotension, Hypertension
Major Drug Interactions
-
Warnings
• Caution in narrow angle glaucoma, prostatic hypertrophy, stenosing peptic ulcer, pyloroduodenal obstruction, or bladder neck obstruction
Recommendations for Patient
-
Pregnancy Considerations
Antihistamine exposure in first trimester not reported to be associated with increased risk of malformations, only recommended for use during pregnancy when benefit outweighs risk
Breastfeeding Considerations
Small (2 to 4 mg), occasional doses of Chlorpheniramine are acceptable during breastfeeding. Larger doses or more prolonged use might cause effects in the infant or decrease the milk supply, particularly in combination with a sympathomimetic such as pseudoephedrine. Single bedtime doses after the last feeding of the day may be adequate for many women and will minimize any effects of the drug. The nonsedating antihistamines are preferred alternatives, though.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: Maybe acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Histamine H1-receptor antagonist in blood vessels, respiratory tract, and gastrointestinal tract
Pharmacokinetics
Peak Plasma Time: 2-3 hr
Excretion: Urine
Contraindications
• Documented hypersensitivity
• Lower respiratory disease, eg, asthma
• Preemies & neonates
• Nursing women
• Acute asthma, sleep apnea
Adverse Reactions
Sedation ranging from mild drowsiness to deep sleep, Dizziness, Lassitude, Anorexia, Nausea, Vomiting, Diarrhea, Constipation, Arrhythmias, Hypotension, Hypertension
Major Drug Interactions
-
Warnings
• Caution in narrow angle glaucoma, prostatic hypertrophy, stenosing peptic ulcer, pyloroduodenal obstruction, or bladder neck obstruction
Recommendations for Patient
-
Pregnancy Considerations
Antihistamine exposure in first trimester not reported to be associated with increased risk of malformations, only recommended for use during pregnancy when benefit outweighs risk
Breastfeeding Considerations
Small (2 to 4 mg), occasional doses of Chlorpheniramine are acceptable during breastfeeding. Larger doses or more prolonged use might cause effects in the infant or decrease the milk supply, particularly in combination with a sympathomimetic such as pseudoephedrine. Single bedtime doses after the last feeding of the day may be adequate for many women and will minimize any effects of the drug. The nonsedating antihistamines are preferred alternatives, though.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: Maybe acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Send to other people